Drug profile · INN
budesonide
BIRESP SPIROMAX
- US status
- approved
- Patents linked
- 5
- News articles
- 0
Quick answer
budesonide (BIRESP SPIROMAX) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: rectal. Current US regulatory status: approved.
Key facts
Related patents
Search patents →-
US 11413296
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 9119863
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8975243
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8497258
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted -
US 8324192
Viscous budesonide for the treatment of inflammatory diseases of the gastrointestinal tract
granted
Frequently asked questions
What is budesonide?
budesonide (BIRESP SPIROMAX) is an FDA-listed pharmaceutical active ingredient. Associated with Teva Pharma GmbH. Route of administration: rectal. Current US regulatory status: approved.
What is the brand name for budesonide?
BIRESP SPIROMAX is a marketed brand name for budesonide. Check FDA Drugs@FDA for the current US label holder and prescribing information.
What is the US approval status of budesonide?
budesonide has approved status in the United States according to our Drugs@FDA-derived records. Verify on the official FDA label before clinical or commercial decisions.